莫西沙星注射液治疗中-重度社区获得性肺炎疗效观察  

Efficacy of intravenous moxifloxacin in treating patients with moderate to severe community-acquired pneumonia

作　　者：张文辉[1] 朱述阳[1] 陈昊[1] 张志亮[1] 张业清[1] 邵华军[1] 

机构地区：[1]徐州医学院附属医院呼吸内科,江苏徐州221002

出　　处：《中国感染与化疗杂志》2006年第5期296-300,共5页Chinese Journal of Infection and Chemotherapy

摘　　要：目的评价莫西沙星注射液治疗中、重度社区获得性肺炎(CAP)的临床应用价值。方法采用前瞻性设计,将82例中、重度CAP患者随机分为两组:①治疗组:40例．给予莫西沙星注射液．400mg静脉滴注．每天1次．疗程为7～14 d;②对照组:42例,给予头孢他啶或头孢哌酮或阿莫西林-舒巴坦+阿奇霉素联合用药．疗程7～14 d;观察细菌清除率、临床疗效、体温降至37．5℃时间、治疗4 d后Fine积分变化、显著好转所需时间、住院天数及不良反应。结果治疗组和对照组有效率及细菌清除率分别为95．0％、92．9％和93．7％、88．2％,两组比较差异无显著性(P>0．05);但治疗组体温降至37．5℃时间、显著好转所需时间、住院时间(分别为2．1±1．0,3．3±1．5和9．1±1．2)d均较对照组(分别为4．2±1．4,5．4±1．3和11．6±1．3)d明显缩短(P均<0．01),治疗组Fine积分值(25．62±5．24)下降较对照组(20．17±4．12)明显．差异有显著性(P<0.01);不良反应少于对照组,有统计学意义。结论新一代喹诺酮类药物莫西沙星可作为经验性治疗中、重度CAP适宜选用的药物。Objective To evaluate the clinical utility of moxifloxacin in the treatment of moderate to severe community-acquired pneumonia （CAP）. Methods A total of 82 patients with moderate to severe CAP were divided into 2 groups： ①treatment group： 40 patients treated with moxifloxacin, 400 mg, qd, for 7-14 days; ②control group： 42 patients treated with ceftazidime or cefoperazone or amoxicillin-sulbactam ± azithromycin for 7 14 days; The bacterial clearance rate, effective rate, the time to defervescence to 37.5 ℃, Fine score at Day 4, the time to obvious improvement, hospitalization stay, and adverse effects were observed. Results The effective rate was 95.0% in the treatment group and 92.9% in control group; bacterial clearance rate was 93.7% and 88.2 % respectively. The difference was not statistically significant between the two groups （P〉0. 05）. The time to defervescence to 37.5℃, the time to obvious improvement, and hospitalization stay in treatment group （2.1 ± 1.0, 3. 3 ± 1.5, and 9.1 ± 1.2, respectively） were shorter than those in control group （4.2 ± 1.4, 5.4 ± 1.3, and 11. 6 ± 1.3, respectively） （P〈0.01）. Fine score decreased after treatment in both groups, but the decrease was more in treatment group （25.62 ±5.24） than in control group （20.17 ± 4.12） （P〈0.01）. The patients had fewer adverse effects in treatment group than in control group. Conclusions Moxifloxacin, a new generation fluoroquinolone agent, can be an appropriate choice in the empiric treatment of moderate to severe CAP patients.

关 键 词：肺炎 社区获得性 治疗 喹诺酮类 莫西沙星 

分 类 号：R563.1[医药卫生—呼吸系统]